Cite
The role of additional chemotherapy prior to autologous HCT in patients with relapse/refractory DLBCL in partial remission—A retrospective multicenter study.
MLA
Shargian, Liat, et al. “The Role of Additional Chemotherapy Prior to Autologous HCT in Patients with Relapse/Refractory DLBCL in Partial Remission—A Retrospective Multicenter Study.” European Journal of Haematology, vol. 110, no. 2, Feb. 2023, pp. 149–56. EBSCOhost, https://doi.org/10.1111/ejh.13884.
APA
Shargian, L., Amit, O., Bernstine, H., Gurion, R., Gafter, G. A., Rozovski, U., Pasvolsky, O., Perets, G., Horowitz, N. A., Halloun, J., Perry, C., Avivi, I., Raanani, P., Yeshurun, M., & Ram, R. (2023). The role of additional chemotherapy prior to autologous HCT in patients with relapse/refractory DLBCL in partial remission—A retrospective multicenter study. European Journal of Haematology, 110(2), 149–156. https://doi.org/10.1111/ejh.13884
Chicago
Shargian, Liat, Odelia Amit, Hanna Bernstine, Ronit Gurion, Gvili, Anat Gafter, Uri Rozovski, Oren Pasvolsky, et al. 2023. “The Role of Additional Chemotherapy Prior to Autologous HCT in Patients with Relapse/Refractory DLBCL in Partial Remission—A Retrospective Multicenter Study.” European Journal of Haematology 110 (2): 149–56. doi:10.1111/ejh.13884.